Stock Events

Gilead Sciences 

$65.68
1969
-$0.49-0.74% Friday 20:00

Statistics

Day High
66.43
Day Low
65.21
52W High
86.09
52W Low
64.33
Volume
5,971,044
Avg. Volume
7,008,985
Mkt Cap
81.83B
P/E Ratio
170.24
Dividend Yield
4.69%
Dividend
3.08

Upcoming

Dividends

4.69%Dividend Yield
10Y Growth
N/A
5Y Growth
4.1%
3Y Growth
2.74%
1Y Growth
2.67%

Earnings

8AugConfirmed
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Next
1.37
2.03
2.68
3.34
Expected EPS
1.616112
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GILD. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap277.35B
AbbVie competes directly with Gilead in the areas of hepatitis C treatments and is also a major player in immunology and oncology.
Merck &
MRK
Mkt Cap327.97B
Merck & Co. offers competitive products in the antiviral space, including treatments for HIV and hepatitis C, directly challenging Gilead's core market.
Pfizer
PFE
Mkt Cap163.65B
Pfizer competes across several therapeutic areas including oncology, immunology, and antiviral drugs, overlapping with Gilead's product portfolio.
Bristol-Myers Squibb
BMY
Mkt Cap83.6B
Bristol Myers Squibb is a key competitor in the oncology and immunology sectors, areas where Gilead Sciences is actively expanding its presence.
Johnson & Johnson
JNJ
Mkt Cap353.71B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the HIV and hepatitis C markets, among others, where Gilead has significant interests.
AMGEN
AMGN
Mkt Cap164.06B
Amgen competes with Gilead in the biopharmaceutical space, particularly in the areas of oncology and inflammatory diseases.
GSK
GSK
Mkt Cap93.51B
GlaxoSmithKline, through its ViiV Healthcare joint venture, is a strong competitor in the HIV treatment market, directly challenging Gilead's leadership.
Novartis
NVS
Mkt Cap220.15B
Novartis competes with Gilead in several areas including oncology and gene therapy, with both companies investing heavily in research and development.
Roche
RHHBY
Mkt Cap177.61B
Roche, through its Genentech unit, competes in the oncology and antiviral markets, areas where Gilead has key products.
Astrazeneca
AZN
Mkt Cap243.51B
AstraZeneca competes with Gilead in the oncology sector, with both companies developing treatments for various cancers.

Analyst Ratings

81.4$Average Price Target
The highest estimate is $105.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
27%
Hold
73%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Show more...
CEO
Daniel O'Day
Employees
18000
Country
US
ISIN
US3755581036
WKN
000885823

Listings